TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34415434

Group type: EXPERIMENTAL
Intervention: Chairside-fabricated ZLS restorations with MMT 0.5-0.74 mm (group 1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Chairside-fabricated ZLS restorations with MMT 0.75-1.0 mm (group 2)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Partial crowns placed on premolars
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Partial crowns placed on molars
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Self-adhesive cement (SAC)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Restorations in group 2 (MMT 0.75-1.0 mm)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Molar partial crowns
Number of subjects: 45
Study: 33693735

Group type: EXPERIMENTAL
Intervention: Animal-based protein food sources (beef sirloin, pork loin, eggs)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Plant-based protein food sources (tofu, kidney beans, peanut butter, mixed nuts)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Animal protein sources (egg and pork)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: All animal protein sources
Number of subjects: 56
Study: 32770482

Group type: EXPERIMENTAL
Intervention: Human astrovirus (HAstV) infection
Number of subjects: 331
Study: 36044915

Group type: EXPERIMENTAL
Intervention: EUS-FNB with MOSE
Number of subjects: 370

Group type: COMPARATOR
Intervention: EUS-FNB with standard technique
Number of subjects: 370
Study: 34425258

Group type: EXPERIMENTAL
Intervention: TSO 1000
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: TSO 2500
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: TSO 7500
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 34970772

Group type: EXPERIMENTAL
Intervention: Restricted survival benefit (RSB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hazard ratio
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Difference of the restricted mean survival times
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Difference in survival proportions at some fixed follow‐up time
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Net chance of a longer survival
Number of subjects: 0
Study: 34175857

Group type: EXPERIMENTAL
Intervention: Oral melatonin 0.3 mg/kg
Number of subjects: 132

Group type: COMPARATOR
Intervention: Midazolam 0.3 mg/kg
Number of subjects: 132

Group type: COMPARATOR
Intervention: Honey (placebo)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: All groups (melatonin, midazolam, placebo)
Number of subjects: 132
Study: 33065218

Group type: EXPERIMENTAL
Intervention: IPS e.max CAD crowns
Number of subjects: 15

Group type: COMPARATOR
Intervention: IPS e.max Ceram hand-veneered zirconia crowns
Number of subjects: 15
Study: 34735198

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Educational control group
Number of subjects: 32
Study: 32885344

Group type: EXPERIMENTAL
Intervention: Intensive community care service (ICCS)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 106
Study: 33156128

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG) surface-treated scleral lenses
Number of subjects: 21

Group type: COMPARATOR
Intervention: Untreated scleral lenses
Number of subjects: 21
Study: 32375843

Group type: EXPERIMENTAL
Intervention: Continuous nursing interventions (group B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Routine nursing care (group A)
Number of subjects: 90
Study: 36349701

Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg subcutaneously
Number of subjects: 68

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 68
Study: 34643736

Group type: EXPERIMENTAL
Intervention: Approach Avoidance Training (AAT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control procedure
Number of subjects: 28
Study: 33768310

Group type: EXPERIMENTAL
Intervention: 80% sorghum + 20% DM pumpkin
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 60% sorghum + 40% DM pumpkin
Number of subjects: 2

Group type: COMPARATOR
Intervention: 100% sorghum
Number of subjects: 2
Study: 32182127

Group type: EXPERIMENTAL
Intervention: Modified Iliotibial Band Tenodesis (MITBT) added to ACL reconstruction (group B)
Number of subjects: 55

Group type: COMPARATOR
Intervention: No further surgery (group A)
Number of subjects: 55
Study: 35141898

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine (LDEX)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 34637889

Group type: EXPERIMENTAL
Intervention: 3D-printed CRDPs
Number of subjects: 15

Group type: COMPARATOR
Intervention: Milled CRDPs
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both milled and 3D-printed CRDPs
Number of subjects: 15
Study: 35042057

Group type: EXPERIMENTAL
Intervention: Talus mobilization-based manual therapy (six sessions of anteroposterior talus mobilization)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham treatment (control group)
Number of subjects: 42
Study: 32271521

Group type: EXPERIMENTAL
Intervention: Normal stereopsis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Partial stereopsis (150 seconds of arc)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Absent stereopsis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Partial stereopsis
Number of subjects: 0
Study: 36455187

Group type: EXPERIMENTAL
Intervention: Decitabine (DAC) 20 mg/m2/d days 1‐5
Number of subjects: 170

Group type: COMPARATOR
Intervention: Hydroxyurea (HY) 1‐4 g/d
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Decitabine (DAC)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Hydroxyurea (HY)
Number of subjects: 170
Study: 36332333

Group type: EXPERIMENTAL
Intervention: e‐Exercise Low Back Pain (self-management intervention)
Number of subjects: 0
Study: 32168870

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 35526605

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (60 mg dose, oral)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Pyridostigmine
Number of subjects: 45
Study: 33332778

Group type: EXPERIMENTAL
Intervention: Combined REGN-COV2 dose groups (2.4 g and 8.0 g)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 275
Study: 32203231

Group type: EXPERIMENTAL
Intervention: Fortified bread with 58FeSO4 consumed with TK
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Fortified bread with 57FeFum consumed with TK
Number of subjects: 17

Group type: COMPARATOR
Intervention: Fortified bread with 58FeSO4 consumed with water
Number of subjects: 17

Group type: COMPARATOR
Intervention: Fortified bread with 57FeFum consumed with water
Number of subjects: 17
Study: 35393332

Group type: EXPERIMENTAL
Intervention: Routine physiotherapy input plus a simple exercise programme completed individually by the patient
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine physiotherapy input
Number of subjects: 0
Study: 34167284

Group type: EXPERIMENTAL
Intervention: New dressing (ND) group - self‐developed low‐temperature boric acid wet dressing, 3 times a day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional dressing (CD) group - normal temperature boric acid solution wet dressing, 3 times a day
Number of subjects: 100
Study: 33028661

Group type: EXPERIMENTAL
Intervention: Experimental treatment of COVID-19 (specific details not provided)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1
Study: 35059187

Group type: COMPARATOR
Intervention: Group A received a standard recommended maintenance dose of 2000 IU daily
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Group B received 125 IU/kg/m2 of vitamin D3
Number of subjects: 230
Study: 33759644

Group type: EXPERIMENTAL
Intervention: Lower body positive pressure (LBPP) applied for 90 min
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Lower body positive pressure (LBPP)
Number of subjects: 21
Study: 33687070

Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 169500
Study: 36376399

Group type: EXPERIMENTAL
Intervention: Ag NPs at 25 µg/mL
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Ag NPs at 50 µg/mL
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Ag NPs at 100 µg/mL
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Ag NPs at 250 µg/mL
Number of subjects: 5

Group type: COMPARATOR
Intervention: Untreated sample
Number of subjects: 5
Study: 34741370

Group type: EXPERIMENTAL
Intervention: Mindfulness-based virtual reality (VR) program (Take-Pause) for 5 minutes
Number of subjects: 110

Group type: COMPARATOR
Intervention: Passive distraction intervention (iPad group) for 5 minutes
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Mindfulness-based virtual reality (VR) program (Take-Pause)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Passive distraction intervention (iPad group)
Number of subjects: 110
Study: 32646941

Group type: EXPERIMENTAL
Intervention: ANGPTL3 inhibition
Number of subjects: 0
Study: 35775517

Group type: EXPERIMENTAL
Intervention: Laparoscopic‐assisted anorectoplasty (LAARP)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Open posterior sagittal anorectoplasty (PSARP)
Number of subjects: 16
Study: 34140199

Group type: EXPERIMENTAL
Intervention: Web-accessible computer role-playing game intervention
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control condition (list of resources)
Number of subjects: 240
Study: 35470199

Group type: EXPERIMENTAL
Intervention: Open dialogue about complementary and alternative medicine (OD‐CAM)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 207
Study: 33451308

Group type: EXPERIMENTAL
Intervention: SMS text-messages intervention (StAR2D)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34348719

Group type: EXPERIMENTAL
Intervention: Baby Steps app
Number of subjects: 23
Study: 32445440

Group type: EXPERIMENTAL
Intervention: Remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days)
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1062

Group type: EXPERIMENTAL
Intervention: Remdesivir
Number of subjects: 1062
Study: 35081799

Group type: EXPERIMENTAL
Intervention: Accelerated rehabilitation group (Group 1)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Traditional rehabilitation group (Group 2)
Number of subjects: 93
Study: 33926246

Group type: EXPERIMENTAL
Intervention: Adolescent self-reported responses
Number of subjects: 2967

Group type: COMPARATOR
Intervention: Parent-reported responses
Number of subjects: 2967
Study: 32353174

Group type: EXPERIMENTAL
Intervention: Six-week physical activity intervention
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 132
Study: 35907370

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% (40 ml)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%, 40 ml)
Number of subjects: 70
Study: 32918459

Group type: EXPERIMENTAL
Intervention: BMI above normal
Number of subjects: 1684

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 1684

Group type: EXPERIMENTAL
Intervention: BMI above normal and obesity
Number of subjects: 1684
Study: 32687539

Group type: EXPERIMENTAL
Intervention: Physician-pharmacist collaboration
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Preferred communication methods
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Perceived roles of pharmacists
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Perceived barriers to collaboration
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Perceptions of collaboration potential
Number of subjects: 518
Study: 36128889

Group type: EXPERIMENTAL
Intervention: B-vitamin intervention (combined folic acid 200 μg, vitamin B12 10 μg, vitamin B6 10 mg, riboflavin 5 mg)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: B-vitamin intervention
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo (active placebo with vitamin D 10 μg)
Number of subjects: 205
Study: 34863304

Group type: EXPERIMENTAL
Intervention: Convalescent plasma in addition to standard of care
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard of care only
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Convalescent plasma group
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard of care group
Number of subjects: 31
Study: 36471399

Group type: EXPERIMENTAL
Intervention: PEGASUS program (intervention)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 16
Study: 33266022

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D (200,000 IU bolus at week 0 followed by 20,000 IU/day for 7 weeks)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D combined with infliximab (5 mg/kg at weeks 0, 2, and 6)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Infliximab alone (5 mg/kg at weeks 0, 2, and 6)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Placebo-infliximab + vitamin D
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo-infliximab + placebo-vitamin D
Number of subjects: 40
Study: 36228567

Group type: EXPERIMENTAL
Intervention: Aronia berry (poly)phenol supplementation
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control (maltodextrin placebo)
Number of subjects: 102
Study: 33933189

Group type: EXPERIMENTAL
Intervention: People living with HIV
Number of subjects: 2017

Group type: COMPARATOR
Intervention: People without HIV
Number of subjects: 2017
Study: 33760368

Group type: COMPARATOR
Intervention: Gout patients
Number of subjects: 330

Group type: COMPARATOR
Intervention: Asymptomatic hyperuricemia patients
Number of subjects: 330

Group type: COMPARATOR
Intervention: Normouricemic controls
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Multivariate diagnostic model using MUVR
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Machine learning algorithms (random forest, support vector machine, logistic regression)
Number of subjects: 330
Study: 33531522

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Interval Training (MIIT)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Inactive Control Group
Number of subjects: 117
Study: 32693310

Group type: EXPERIMENTAL
Intervention: Knowledge of Performance (KP) feedback
Number of subjects: 14

Group type: COMPARATOR
Intervention: Knowledge of Results (KR) + Knowledge of Performance (KP) feedback on 1 day per week and KR feedback on the other 3 days per week
Number of subjects: 14
Study: 34732114

Group type: EXPERIMENTAL
Intervention: DEX plus midazolam (DM group)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: DEX plus propofol (DP group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both groups (DM and DP)
Number of subjects: 50
Study: 34814584

Group type: EXPERIMENTAL
Intervention: 20 µg hepatitis B vaccination
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: 60 µg hepatitis B vaccination
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccination in patients with CD4 <350 cells/µl
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccination in patients with CD4 ≥350 cells/µl
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Follow-up from 6 months to 3 years after vaccination in patients with CD4 <350 cells/µl
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Follow-up from 6 months to 3 years after vaccination in patients with CD4 ≥350 cells/µl
Number of subjects: 182
Study: 33672197

Group type: EXPERIMENTAL
Intervention: No self-perceived need of dental care
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Lower DMFT index
Number of subjects: 344

Group type: COMPARATOR
Intervention: Frequent tooth-brushing (18.4% reported)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Need for dental care (39.9% reported)
Number of subjects: 344
Study: 32111701

Group type: EXPERIMENTAL
Intervention: Telehealth coaching intervention (phone calls every 2 weeks for 3 months, followed by 3 months of tailored text messages)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care for 3 months, followed by nontailored educational text messages for 3 months
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Telehealth coaching intervention
Number of subjects: 80
Study: 32776988

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 10
Study: 36419043

Group type: EXPERIMENTAL
Intervention: Group A: Low-dose CT scans and 3D models printed before inexperienced surgeons performed surgeries
Number of subjects: 80

Group type: COMPARATOR
Intervention: Group B: Standard-dose CT scans and 3D models printed before experienced surgeons performed surgeries
Number of subjects: 80

Group type: COMPARATOR
Intervention: Group C: Standard-dose CT scans, operations performed by inexperienced surgeons
Number of subjects: 80

Group type: COMPARATOR
Intervention: Group D: Standard-dose CT scans, operations performed by experienced surgeons
Number of subjects: 80
Study: 34652861

Group type: EXPERIMENTAL
Intervention: Curcumin
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 132
Study: 32012257

Group type: EXPERIMENTAL
Intervention: Family-Focused Treatment for Adolescents (FFT-A) - 21 sessions
Number of subjects: 144

Group type: COMPARATOR
Intervention: Enhanced Care (EC) - 3 sessions
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Family-Focused Treatment for Adolescents (FFT-A)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Enhanced Care (EC)
Number of subjects: 144
Study: 36169179

Group type: EXPERIMENTAL
Intervention: Early referral to palliative care
Number of subjects: 15

Group type: COMPARATOR
Intervention: Discretionary referral to palliative care
Number of subjects: 15
Study: 36279930

Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 2467

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2467
Study: 32854751

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 33441158

Group type: EXPERIMENTAL
Intervention: 3 g/day Omega-3 supplementation (N-3, n = 7)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (PLA, n = 7)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: N-3 supplementation (n = 7)
Number of subjects: 14
Study: 32083365

Group type: EXPERIMENTAL
Intervention: Wearable cardioverter-defibrillator (WCD) compliance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: WCD compliance predictors
Number of subjects: 0
Study: 34431196

Group type: EXPERIMENTAL
Intervention: Opt-out delivery of point-of-care (POC) HIV-1 nucleic acid testing (NAAT)
Number of subjects: 2874

Group type: COMPARATOR
Intervention: Standard provider-initiated HIV testing using rapid tests
Number of subjects: 2874
Study: 34015241

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg three times per week
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo three times per week
Number of subjects: 25
Study: 33891328

Group type: EXPERIMENTAL
Intervention: Saline
Number of subjects: 48

Group type: COMPARATOR
Intervention: Air
Number of subjects: 48
Study: 36002117

Group type: EXPERIMENTAL
Intervention: 5,000 mg ASA orally once daily from D 120 until parturition (group ASA1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 5,000 mg ASA orally twice daily from D 285 until parturition (group ASA2)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 5,000 mg lactose orally once daily from D 120 until parturition (group C)
Number of subjects: 16
Study: 32663269

Group type: EXPERIMENTAL
Intervention: Ridge Expansion (RE)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Non-Ridge Expansion (NE) Control
Number of subjects: 12
Study: 32160058

Group type: EXPERIMENTAL
Intervention: Whole‐body cryotherapy (WBC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Contrast‐water therapy (CWT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 12
Study: 35051263

Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 153

Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 153
Study: 32207354

Group type: EXPERIMENTAL
Intervention: Pro-inflammatory cytokines (IL-6, IL-12p70, IL-17, TNF-α)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Anti-inflammatory cytokines (IL-10, TGF-β1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cytokine levels among survivors and nonsurvivors
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cytokine levels correlation with SOFA and VIS
Number of subjects: 50
Study: 33947195

Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus reuteri (DSM 17938 and ATCC PTA 6475)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 35932798

Group type: EXPERIMENTAL
Intervention: Advance care plans established before pneumonia
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Changes in advance care plans after pneumonia
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Changes in treatment plans after pneumonia
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Severity of illness
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Influence of family members in decision making
Number of subjects: 429
Study: 33662285

Group type: EXPERIMENTAL
Intervention: 60 Gy in 40 fractions of thoracic radiotherapy
Number of subjects: 170

Group type: COMPARATOR
Intervention: 45 Gy in 30 fractions of thoracic radiotherapy
Number of subjects: 170
Study: 35189750

Group type: EXPERIMENTAL
Intervention: NBS! teacher-implemented
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: NBS! community aide-implemented
Number of subjects: 281

Group type: COMPARATOR
Intervention: Control
Number of subjects: 281
Study: 33449860

Group type: EXPERIMENTAL
Intervention: HU00701 (0.01% cyclosporin A + 3% trehalose)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: HU007 (0.02% cyclosporin A + 3% trehalose)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114

Group type: COMPARATOR
Intervention: Reference group
Number of subjects: 114
Study: 33594720

Group type: EXPERIMENTAL
Intervention: Pedometer-supported walking and telemonitoring
Number of subjects: 67
Study: 32012062

Group type: EXPERIMENTAL
Intervention: YouthCHAT, an Electronic Composite Psychosocial Screener
Number of subjects: 0